Retraction Notice to: Cancer-Related Mutations Identified in Primed and Naive Human Pluripotent Stem Cells (Cell Stem Cell (2021) 28(1) (164–169.e2), (S193459092030552X), (10.1016/j.stem.2020.11.014))

(Cell Stem Cell 25, 456–461; October 3, 2019) In our Synthesis article we published a methodology to identify point mutations in cancer-related genes utilizing RNA-seq data, demonstrating cancer-related mutations in human pluripotent stem cells (hPSCs) and suggesting a higher mutation rate in naive cells compared with their primed counterparts. In a subsequent Matters Arising article, Stirparo et al. (https://doi.org/10.1016/j.stem.2020.11.014) re-analyzed the same data of naive and primed cells and convincingly showed that many of the point mutations mistakenly identified in naive-converted samples stemmed from a high contamination of mouse embryonic fibroblast sequences in the original RNA-seq samples. Eliminating these sequences reduced the overall number of cancer-related mutations identified in hPSCs and abolished the differences identified between naive and primed cells. We thus retract our original Synthesis article and publish a Letter describing the revised methodology and the correct cancer-related mutations in primed hPSCs (see https://doi.org/10.1016/j.stem.2020.11.013). We sincerely apologize to our colleagues for the unintentional mistake in our original methodology, and we direct them to our Letter (https://doi.org/10.1016/j.stem.2020.11.013) and to the Matters Arising article by Stirparo et al. (https://doi.org/10.1016/j.stem.2020.11.014), which together correctly report on cancer-related mutations in primed and naive hPSCs, respectively.